{"id":108654,"date":"2021-05-26T10:50:55","date_gmt":"2021-05-26T10:50:55","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=108654"},"modified":"2021-05-26T10:50:55","modified_gmt":"2021-05-26T10:50:55","slug":"fetal-hydantoin-syndrome","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/","title":{"rendered":"Fetal hydantoin syndrome"},"content":{"rendered":"<p>Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to those of several other AEDs, including carbamazepine, valproic acid, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome. As with most teratogens, major damage occurs from exposure early in prenatal development.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-108654","post","type-post","status-publish","format-standard","hentry","category-f"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fetal hydantoin syndrome - Definition of Fetal hydantoin syndrome<\/title>\n<meta name=\"description\" content=\"Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to those of several other AEDs, including carbamazepine, valproic acid, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome. As with most teratogens, major damage occurs from exposure early in prenatal development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fetal hydantoin syndrome - Definition of Fetal hydantoin syndrome\" \/>\n<meta property=\"og:description\" content=\"Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to those of several other AEDs, including carbamazepine, valproic acid, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome. As with most teratogens, major damage occurs from exposure early in prenatal development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T10:50:55+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/\",\"name\":\"Fetal hydantoin syndrome - Definition of Fetal hydantoin syndrome\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2021-05-26T10:50:55+00:00\",\"dateModified\":\"2021-05-26T10:50:55+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to those of several other AEDs, including carbamazepine, valproic acid, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome. As with most teratogens, major damage occurs from exposure early in prenatal development.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fetal hydantoin syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fetal hydantoin syndrome - Definition of Fetal hydantoin syndrome","description":"Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to those of several other AEDs, including carbamazepine, valproic acid, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome. As with most teratogens, major damage occurs from exposure early in prenatal development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Fetal hydantoin syndrome - Definition of Fetal hydantoin syndrome","og_description":"Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to those of several other AEDs, including carbamazepine, valproic acid, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome. As with most teratogens, major damage occurs from exposure early in prenatal development.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/","og_site_name":"Glossary","article_published_time":"2021-05-26T10:50:55+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/","name":"Fetal hydantoin syndrome - Definition of Fetal hydantoin syndrome","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2021-05-26T10:50:55+00:00","dateModified":"2021-05-26T10:50:55+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"Fetal hydantoin syndrome (FHS) is caused by the anticonvulsant drug (AED) phenytoin (Dilantin). Phenytoin is a prenatal teratogen, causing a variety of physical defects, including infant failure to thrive, dysmorphic facies and other physical abnormalities, growth deficiency, and mental retardation, usually mild. The effects, particularly craniofacial, of prenatal exposure to phenytoin are so similar to those of several other AEDs, including carbamazepine, valproic acid, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome. As with most teratogens, major damage occurs from exposure early in prenatal development.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-hydantoin-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Fetal hydantoin syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=108654"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108654\/revisions"}],"predecessor-version":[{"id":108655,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108654\/revisions\/108655"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=108654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=108654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=108654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}